Brief: Ocumension Therapeutics Says OT-502 Approved By NMPA To Conduct A Phase III Clinical Trial In China
14/09/2021 15:00
Sept 14 (Reuters) - Ocumension Therapeutics 1477.HK :
* OT-502 APPROVED BY CENTER FOR DRUG EVALUATION OF NMPA TO
CONDUCT
A PHASE III CLINICAL TRIAL IN CHINA
Further company coverage: 1477.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Ocumension Therapeutics
See all newsBrief: Ocumension Therapeutics Says NMPA Accepts NDA For OT-301 (NCX 470, Bimatoprost Grenod)
Brief: Ocumension Therapeutics Says Dexamethasone Intraocular Suspension Application Accepted By NMPA
Brief: Ocumension Therapeutics Says HY Adjusted Net Loss Rmb57.5 Million
China's Ocumension Therapeutics H1 revenue surges on higher ophthalmic product sales
Ocumension jumps most in three months on China nod for new drug application